Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amplia Therapeutics ( (AU:ATX) ) has issued an announcement.
Amplia Therapeutics Limited has announced the quotation of 10,869,567 fully paid ordinary securities on the Australian Securities Exchange (ASX) under the code ATX, effective September 1, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s financial flexibility and market presence, which could positively impact its strategic initiatives and stakeholders.
The most recent analyst rating on (AU:ATX) stock is a Buy with a A$0.42 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutics for the treatment of cancer and fibrotic diseases. The company is dedicated to advancing its pipeline of drug candidates to address unmet medical needs in these areas.
YTD Price Performance: 85.39%
Average Trading Volume: 7,254,682
Technical Sentiment Signal: Buy
Current Market Cap: A$82.69M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.